Affiliation:
1. ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, TIBBİ ONKOLOJİ BİLİM DALI
2. MEDİCANA İNTERNATİONAL İZMİR HASTANESİ TIBBİ ONKOLOJİ
Abstract
In this study, the effect of demographic, laboratory and clinicopathological parameters along with neutrophil-lymphocyte ratio (NLR) on prognosis and survival and correlation with other parameters was researched in patients with malignant melanoma (MM) diagnosis. In our study, 107 patients monitored for MM diagnosis in Eskişehir Osmangazi University Medical Oncology clinic from 2010-2017 were retrospectively assessed. Age, gender, LDH level, pathological parameters, BRAF mutation status, neutrophil-lymphocyte ratio (NLR) and the effects of these parameters on overall survival (OS) and disease-free survival (DFS) and correlations with each other were researched. At time of diagnosis, 86% of patients were in the early stage. The dominant types identified were cutaneous MM and nodular MM. Median NLR cut-off value was identified as 1.97. All non-cutaneous MM cases were BRAF negative (p<0.0001). High NLR was associated with advanced stage (p=0.001), advanced age (p=0.008), ulceration presence (p=0.011), and high mitosis count (p=0.05). High NLR (p<0.0001), high LDH level (p=0.04), increased Breslow thickness (p=0.01), increased Clark level (p=0.01), high mitosis count (p=0.02), and lymph node (LN) involvement (p=0.04) were correlated with significantly shorter OS durations. Cox multivariate regression analysis identified the most effective independent parameters on OS were LN involvement (HR: 3.4, p=0.01) and high NLR (HR: 4.6, p=0.04). Nodal involvement was also identified as the most predictive independent parameter for recurrence (HR: 3.2, p=0.03). In addition to classic parameters, NLR appears to be a biomarker which can predict prognosis. Patients with nodal involvement and high NLR values should be monitored more closely in clinics. Data require support with broad-scale studies.
Publisher
Osmangazi Journal of Medicine
Subject
Microbiology (medical),Immunology,Immunology and Allergy
Reference59 articles.
1. 1. Matthews NH, Li W-Q, Qureshi AA, Weinstock MA, Cho E. Epidemiology of melanoma. Cutaneous Melanoma: Etiology and Therapy. Codon Publications; 2017;3-22.
2. 2. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CAJJoID. Increasing burden of melanoma in the United States. 2009;129(7):1666-74.
3. 3. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. Journal of leukocyte biology. 2002;72(1):9-18.
4. 4. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161(7):1681-96.
5. 5. Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. 2016;17(9):1248-60.